/
AVR
$9.78+$0.09 (+0.93%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$943.2M
97M shares
52-week range
$2.85 – $10.56
90% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
0.85%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$4.18
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $5.5M | $5.8M | $3.2M | $2.7M | $2.7M | $1.9M |
| Cost of revenue | $2.1M | $3.9M | $2.9M | $1.9M | $1.4M | $2.2M |
| Gross profit | $3.4M | $1.9M | $298.4K | $876.8K | $1.3M | −$317.0K |
| Gross margin | 61.5% | 32.7% | 9.3% | 32.1% | 46.8% | -16.6% |
| R&D | $3.6M | $10.0M | $17.6M | $31.0M | $51.5M | $69.1M |
| Operating income | −$13.3M | −$16.9M | −$31.1M | −$48.1M | −$78.4M | −$93.9M |
| EBITDA | −$14.1M | −$15.5M | −$29.1M | −$45.5M | −$74.4M | −$92.5M |
| Net income | −$11.8M | −$17.2M | −$30.6M | −$46.0M | −$76.3M | −$94.1M |
| Net margin | -215.8% | -294.5% | -954.9% | -1682.8% | -2822.5% | -4921.3% |
| EPS (diluted) | -0.33 | -0.48 | -0.85 | -1.28 | -3.77 | -4.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-1.08 | $-1.11–$-1.04 | 2 |
| 2027 | $17M | $-0.98 | $-1.59–$-0.50 | 1 |
| 2028 | $21M | $-0.82 | $-1.33–$-0.41 | 1 |
| 2029 | $166M | $-0.68 | $-1.10–$-0.34 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Anteris Technologies Global Corp. Common Stock
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
www.anteristech.com- Employees
- 174
- IPO / List date
- Dec 13, 2024
- HQ
- EAGAN, MN
Held by traders on TradeandTell
No one on the platform currently holds AVR.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AVR as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2006-02-21 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded AVR yet.
